Abbott Laboratories is a global healthcare leader founded in 1888 in Chicago by Dr. Wallace C. Abbott, a physician-pharmacist who pioneered standardized, scientifically validated botanical and alkaloidal medicines. Originally named Abbott Alkaloidal Company, the firm adopted its current name in 1915 and has since evolved from a U.S.-centric pharmaceutical manufacturer into one of the world’s most diversified and integrated healthcare companies. Its enduring mission—articulated as 'Helping people live fuller, healthier lives'—has guided strategic decisions across generations, emphasizing scientific rigor, ethical stewardship, and equitable access. Abbott played pivotal roles during major public health crises, including developing early antiseptics during World War I, pioneering oral rehydration therapy for cholera in the 1970s, launching the first FDA-approved rapid HIV test in the 1990s, and deploying over 1 billion BinaxNOW™ rapid antigen tests globally during the COVID-19 pandemic. The company’s foundational commitment to evidence-based innovation, regulatory excellence, and long-term patient outcomes—not just short-term financial metrics—has cemented its reputation as a trusted partner to clinicians, payers, governments, and patients worldwide.
Abbott operates through four highly synergistic business segments: Established Pharmaceutical Products, Diagnostics, Nutrition, and Medical Devices. The Established Pharmaceuticals segment delivers high-quality, affordable generic therapies across therapeutic areas including pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, migraine, depression, gynecological disorders, and hormone replacement therapy; it also markets clarithromycin, seasonal influenza vaccine, and colon motility regulators. The Diagnostics segment encompasses a comprehensive portfolio: core laboratory systems (immunoassay, clinical chemistry, hematology, transfusion medicine); molecular diagnostics platforms (e.g., m2000™ system automating nucleic acid extraction, purification, and real-time PCR detection); point-of-care solutions (i-STAT®, Alere™); blood gas, chemistry, electrolyte, coagulation, and immunoassay cartridges; rapid lateral flow assays (BinaxNOW®); molecular POC testing for HIV, SARS-CoV-2, influenza A/B, RSV, and strep A; cardiometabolic analyzers; and workplace drug and alcohol screening tools. The Nutrition segment offers science-backed pediatric formulas (Enfamil®, Similac®), adult medical nutrition (Ensure®, Glucerna®, Pedialyte®), and specialized clinical nutrition for metabolic and gastrointestinal conditions. The Medical Devices segment includes market-leading cardiovascular technologies—rhythm management (pacemakers, ICDs), electrophysiology (mapping/ablation), heart failure (HeartMate® VADs), structural heart (MitralClip®, TriClip®, Amplatzer™), vascular interventions—and diabetes care (FreeStyle Libre® continuous glucose monitoring systems), as well as neuromodulation devices (Proclaim®) for chronic pain and movement disorders. Abbott also develops cancer screening biomarkers (e.g., Elecsys® BRAF V600E) and collaborates on multi-cancer early detection (Galleri™ test).
With operations in over 160 countries and annual revenue exceeding $45 billion, Abbott maintains a uniquely balanced global footprint. In high-income markets—including the U.S., EU, Japan, and Canada—it leads in premium medical devices and complex diagnostics, commanding strong pricing power and deep payer relationships. In emerging markets—such as India, Brazil, South Africa, Indonesia, and Turkey—its established pharmaceuticals and nutrition businesses generate scale, margin stability, and critical public health impact. In Turkey specifically, Abbott has operated since the 1950s, with commercial offices in Istanbul and Ankara, a regional distribution hub, and a state-of-the-art manufacturing facility in Gebze opened in 2022. Its customer base spans diverse demographics: infants and children (nutrition), adolescents and adults (diabetes and cardiovascular devices), aging populations (Alzheimer’s diagnostics, neuromodulation), clinicians (lab and POC systems), hospitals and labs (enterprise diagnostic contracts), and governments (WHO Essential Medicines procurement). Abbott supplies over 20 products listed on the WHO Model List of Essential Medicines, making it indispensable to national health programs in low- and middle-income countries.
Abbott’s forward-looking strategy rests on three interlocking pillars: (1) Expanding into novel therapeutic frontiers beyond traditional device domains—such as non-dialysis kidney disease (e.g., FGF23 inhibitors) and neurodegenerative therapeutics; (2) Accelerating digital health integration—leveraging AI-driven predictive analytics (e.g., LibreLinkUp® glucose forecasting), cloud-based remote monitoring platforms, and interoperable EHR connectivity; (3) Advancing environmental and social sustainability—targeting carbon neutrality by 2030, achieving zero waste to landfill across all manufacturing sites, and reducing plastic packaging by 25% by 2025. Strategic acquisitions—including St. Jude Medical (2017) and Cardiovascular Systems, Inc. (2022)—have significantly strengthened its structural heart and peripheral vascular portfolios. R&D investment priorities for 2025–2030 allocate 40% to digital health, 30% to cardiovascular and metabolic innovation, and 20% to oncology and neurology diagnostics. Regionally, Abbott partners with Turkey’s Ministry of Health on nationwide diabetes education initiatives and free Libre device distribution through 'Healthy Life Centers', exemplifying its commitment to scalable, locally adapted healthcare transformation.